This Space Biotech Just Got $1.1M to Hunt for Cures in Orbit

Jan de Vries · 2026-08-11

What if the next big breakthrough in medicine doesn't come from a lab on Earth, but from a tiny capsule floating hundreds of miles above our heads? That's the bet Exobiosphere is making, and it just got a serious vote of confidence. The Luxembourg-based space BioTech startup, which focuses on drug discovery and biomedical research in microgravity, has secured $1.1 million in non-dilutive funding. The money comes through Luxembourg's Jeune Entreprise Innovante (JEI) aid scheme, a program designed to give young, research-heavy companies the fuel they need to grow without giving up equity. The grant, handed out by the Ministry of the Economy, will be used to expand the company's commercial operations and scale up its orbital high-throughput screening platform. In plain English: they're getting ready to do a lot more science in space, and they need the resources to make it happen. ### Why Space Matters for Medicine You might be wondering: why would anyone want to run medical experiments in space? It sounds like something out of a sci-fi movie, but the logic is actually pretty grounded. Here's the thing: microgravity does wild things to biology. It accelerates processes that take forever to unfold on Earth. We're talking about cellular senescence (that's the aging of cells), immune dysregulation, neuronal development, and even tumor aggressiveness. These processes can take years or decades to show up in a normal lab setting, but in space, they happen much faster. That speed is a game-changer. It means researchers can actually watch disease mechanisms unfold in real time and see how drugs respond in ways that standard in-vitro models just can't capture. It's like being able to fast-forward a movie to see the ending instead of waiting for it to happen in real life. ### Meet the Orbital High-Throughput Screening System Exobiosphere's core product is something called the Orbital High-Throughput Screening (OHTS) system. It sounds technical, and it is, but here's the simple version: it's an automated lab that runs in orbit. The system can handle more than 2,000 simultaneous automated experiments per mission. Everything is mirrored back to Earth-based control systems in real time, so the team can watch what's happening from the ground. The platform feeds and differentiates cells, dispenses toxic compounds or therapeutic drugs, processes samples autonomously, and even performs plate-reader and microscopy-based readouts. What does that mean for real-world applications? Think complex 3D disease modeling, automated stem cell differentiation, and compound potency testing. These are the kinds of things that could lead to new treatments for some of the hardest-to-tackle diseases we face. ### The Team Behind the Mission Exobiosphere was founded in 2024 by Kyle Acierno, who serves as CEO, along with Dr. Bruno Santos and Dr. Olivia Borgue. They're building what they describe as the world's first standardized space-based high-throughput testing platform. The goal is to give pharmaceutical and BioTech companies the ability to run automated experiments in orbit at scale, and maybe, just maybe, find some "cures from space." Acierno seems genuinely pumped about the grant. "This grant lands at exactly the right moment and makes a real difference for a company at our stage," he said. "It allows us to expand our commercial activities, strengthen our team, and bring our technological offer to more pharmaceutical and biotech partners around the world." He also gave a shout-out to the local ecosystem, saying, "We're grateful for the continued support of the Luxembourg innovation ecosystem and Ministry of Economy." ### What the JEI Scheme Actually Does The JEI scheme is pretty clever. It pairs non-dilutive public funding with private investment to help young companies push into their next phase of growth. The program co-finances up to 70% of a company's estimated financing needs over a period of up to three years, capped at $1.1 million. To qualify, applicants need to hold an innovation certificate from Luxinnovation, which confirms their status as an innovative enterprise. Exobiosphere already had that certificate lined up before the grant, so they were ready to go. ### What's Next for Exobiosphere? The company says the capital will accelerate its commercial expansion, strengthen internal operations, and grow international business development and marketing activity. It'll also support the scale-up of its proprietary orbital high-throughput screening platform. As for the science, Exobiosphere is exploring therapeutic areas including oncology, aging, neurodegeneration, radiation response, inflammation, and cardiovascular disease. That's a pretty broad net, but that's kind of the point. The platform is designed to be versatile, and the team wants to see where the science takes them. It's still early days, but the potential here is enormous. If microgravity really can accelerate disease modeling in the way Exobiosphere believes, we could be looking at a whole new era of drug discovery. And that's something worth keeping an eye on, whether you're in biotech or just someone who cares about where the next big medical breakthrough is coming from. For now, the team is focused on scaling up and bringing their technology to more partners around the world. The funding gives them the runway to do exactly that. And honestly? It's hard not to root for a company that's literally reaching for the stars to solve some of our most pressing health challenges.